Compare CPHI & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHI | MYO |
|---|---|---|
| Founded | N/A | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 44.8M |
| IPO Year | 2008 | 2017 |
| Metric | CPHI | MYO |
|---|---|---|
| Price | $0.98 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.0M | 646.3K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,144,268.00 | ★ $1,000,000,000.00 |
| Revenue This Year | N/A | $9.10 |
| Revenue Next Year | N/A | $13.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.38 | $0.61 |
| 52 Week High | $19.19 | $1.89 |
| Indicator | CPHI | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 65.54 |
| Support Level | $0.54 | $0.69 |
| Resistance Level | $1.43 | N/A |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 5.01 | 83.82 |
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.